Archives
-
o2h Ventures Named Runner-Up for Best EIS Investment Manager — Specialist at the 2025 Growth Investor Awards
13 November, 2025
-
o2h Ventures Participates in Oversubscribed Seed Round to Advance CamGene Therapeutics’ RNA-Based Medicines
03 November, 2025
-
o2h Ventures Portfolio Update: Monument Therapeutics Reaches Landmark Milestone in Schizophrenia
23 August, 2025
-
o2h Ventures Recognised at EISA Impact Awards 2025 for Exonate’s Topical Eye-Drop for Diabetic Retinopathy
20 June, 2025
-
o2h Ventures Shortlisted for Two EISA Awards 2025: Impact and Ecosystem Champion
31 May, 2025
-
o2h Ventures Makes SEIS investment in Sansanima, A University of Sheffield Spinout Developing Alternatives to Animal Testing
28 May, 2025
-
o2h Ventures Shortlisted for ‘Seed VC of the Year’ at UKBAA Angel Investment Awards 2025
14 May, 2025
-
o2h Ventures Backs Enedra Therapeutics, Targeting Complex Cancers
07 May, 2025
-
o2h Ventures Makes a Follow-on Investment in Qkine, the Cambridge-based Specialist in Growth Factor Manufacturing
21 March, 2025
invest in the growth potential of UK life science & AI